Currently, there are 141.59M common shares owned by the public and among those 117.88M shares have been available to trade.
The company’s stock has a 5-day price change of -23.41% and -34.85% over the past three months. MRVI shares are trading -42.39% year to date (YTD), with the 12-month market performance down to -38.55% lower. It has a 12-month low price of $3.91 and touched a high of $11.56 over the same period. MRVI has an average intraday trading volume of 2.00 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -29.60%, -37.58%, and -57.04% respectively.
Institutional ownership of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) shares accounts for 87.06% of the company’s 141.59M shares outstanding.
It has a market capitalization of $792.94M and a beta (3y monthly) value of -0.05. The earnings-per-share (ttm) stands at -$1.65. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.26% over the week and 8.33% over the month.
Analysts forecast that Maravai LifeSciences Holdings Inc (MRVI) will achieve an EPS of -0.04 for the current quarter, -0.02 for the next quarter and -0.07 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.06 while analysts give the company a high EPS estimate of -0.06. Comparatively, EPS for the current quarter was 0.01 a year ago. Earnings per share for the fiscal year are expected to decrease by -360.81%, and 14.33% over the next financial year.
Goldman coverage for the Maravai LifeSciences Holdings Inc (MRVI) stock in a research note released on December 05, 2024 offered a Sell rating with a price target of $4.25. Wells Fargo on their part issued Overweight rating on August 28, 2024.
